1. �й�ҽѧ��ѧԺƤ�����о���
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���

����ͷ��������Ⱦ��ȫ�����صĹ����������⡣��������ͷ������Ԥ��������ijɹ�Ϊ����ͷ��������Ⱦ��Ԥ��������ṩ��Ҫ���ԣ������������֢��Ⱦ�����¼�����Ч������ͷ������������������з���Ϊ������ȵ㡣��Ŀǰ�о�������ͷ��������������������������硢�����硢�������硢DNA���硢RNA�����ϸ��������о����и�����Ϊ����ͷ�����������о��ṩ�ο������У��������簲ȫ�Ժá��������ϸ����ԭ���ƿ���ͨ����������������Ч��Ӧ����Ŀǰ�ٴ�Ӧ�õ���ѡ��

Human papillomavirus ��HPV�� infection has been a serious public health issue worldwide. Recent years prophylactic HPV vaccines have been proved to be successful as an important strategy for HPV prevention and control. However, prophylactic HPV vaccines do not have therapeutic effects against pre-existing HPV infection and HPV-associated diseases, so it is important and urgent to develop effective therapeutic vaccines against HPV. This article reviews current progress of therapeutic HPV vaccines, including vector-based vaccines, peptide and protein based vaccines, DNA-based vaccines, RNA vaccines and whole cell vaccines. In consideration of safety, no restriction of HLA, enhanced potency by adjuvant, protein based vaccines attract scientists' eyes in clinical application in the near future.

[1]Parkin DM.The global health burden of infection-associated cancers in the year 2002[J].Int J Cancer,2006,118(12):3030-3044 [2]Trimble C.L.��Frazer IH[J].Development of therapeutic HPV vaccines. Lancet Oncol,2009,10(10):975-980 [3]Munoz N, Bosch FX, de Sanjose S, et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer[J].N Engl J Med,2003,348(6):518-527 [4]zur Hausen H.Papillomaviruses and cancer: from basic studies to clinical application[J].Nat Rev Cancer,2002,2(5):342-350 [5]Crook T., Morgenstern J[J].P., Crawford L. et al. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. The EMBO Journal,1989,8(2):513-519 [6]Munger K, Howley PM.Human papillomavirus immortalization and transformation functions[J].Virus Res,2002,89(2):213-228 [7]Mahdavi A��Monk BJ.Vaccines against human papillomavirus and cervical cancer: promises and challenges[J].Oncologist,2005,10(7):528-538 [8]Hung CF, Ma B, Monie A., et al[J].Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin. Biol.Ther,2008,8(4):421-439 [9]Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al.Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice[J].Cancer Immunol Immunother,2007,56(7):997-1007 [10]Liao J.B., Publicover J[J]., Rose J.K.��et al. Single-Dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein._Clin. Vaccine Immunol,2008,15(5):817-824 [11]Riezebos-Brilman A, Regts J, Freyschmidt E-J, et al.Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7 transgenic mice[J].Gene Therapy,2005,12(18):1410-1414 [12]Sewell D.A.��Pan ZK, Paterson Y[J].Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine,2008,26(41):5315-5320 [13]Kenter GG., Welters M[J].J.P., Valentijn A.R.P.M., et al. Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. N Engl J Med,2009,361(19):1838-1847 [14]Karanam B, Gambhira R, Peng SW, et al.Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity[J].Vaccine,2009,27(7):1040-1049 [15]Chuang CM, Hoory T, Monie A, et al.Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells[J].Vaccine,2009,27(5):684-689 [16]Huang B, Mao CP, Peng SW, et al.RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency[J].Hum Gene Ther,2008,19(8):763-773 [17]Kim TW, Hung CF, Juang J, et al.Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death[J].Gene Ther,2004,11(3):336-342 [18]Kim JH, Kang TH, Noh KH et al.Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8+ T cell-mediated cell death[J].Immunology Letters,2009,122(1):58-67 [19]Kang TH, Lee JH, Bae HC, et al.Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments[J].Immunology Letters,2006,106(2):126-134 [20]Santin AD, Bellone S., Palmieri M[J]., et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol,2008,82(4):1968-1979 [21]Lin CT, Hung CF, Juang J��et al.Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles[J].Mol Ther,2003,8(4):559-566 [22]Kang TH, Lee JH, Song CK, et al.Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination[J].Cancer Res,2007,67(2):802-811